DoMore Diagnostics expands its Scientific Advisory Board with leading oncologists Dr. Jeanine Roodhart and Dr. Frank Sinicrope
OSLO – October 31, 2024 – DoMore Diagnostics, a leader in AI and deep learning precision medicine for cancer, announces the addition of internationally recognized colorectal cancer researchers and clinicians Dr. Jeanine Roodhart (UMC Utrecht) and Dr. Frank Sinicrope (Mayo Clinic) to its Scientific Advisory Board (SAB).
Jeanine Roodhart, MD PhD, is a medical oncologist and associate professor in the Department of Medical Oncology at the University Medical Centre Utrecht, University of Utrecht, in the Netherlands. She is an internationally recognized expert in colorectal cancer, specializing in both clinical and translational research and the design of (early phase) clinical trials. Her research is focused on the personalization of treatment for both non-metastatic and metastatic colorectal cancer. She is the lead investigator on multiple biomarker studies, which are exploring different molecular markers, ctDNA, organoids and digital pathology in order to optimize patient selection. Additionally, she is engaged in optimizing disease models and the development of novel personalized treatments. She is the principal investigator on numerous phase I-III clinical trials.
Frank A. Sinicrope, MD FACP, is currently a professor of oncology and medicine at the Mayo Clinic Alix School of Medicine and member of the Mayo Comprehensive Cancer Center in Rochester, MN. Dr. Sinicrope is an internationally recognized expert in gastrointestinal oncology and has a longstanding funded research program with a focus on colorectal cancer. He is a Clinical Investigator of the Mayo Foundation and formerly led the GI Cancer Program within the 3-site Mayo Cancer Center. He is a current member of the National Cancer Institute Colon Cancer Task Force and served 2 terms on the NCI GI Cancer Steering Committee. Currently, he holds multiple committee memberships within the Alliance for Clinical Trials in Oncology including the Executive Committee for the Translational Research Program. Dr. Sinicrope’s research interests include multi-omic analysis of colorectal cancer and predictive and prognostic biomarkers, including the use of deep learning methods. He has over 200 peer reviewed manuscripts and is a principal investigator on active clinical trials. He received his training at MD Anderson Cancer Center and the University of Chicago.
Torbjørn Furuseth, MD, CEO and Co-Founder of DoMore Diagnostics, said: “We are proud to welcome Drs. Roodhart and Sinicrope to our scientific advisory board, both known as leading international experts in colorectal cancer research and clinical practice. Their contribution will be invaluable as we go forward in our meticulous work in preparing our digital biomarker Histotype Px® Colorectal for market entry making it available for clinicians and patients worldwide.”
DoMore Diagnostics’ SAB consists of internationally renowned colorectal cancer specialists:
Dr. John L. Marshall, MD, Physician Executive Director, MedStar Washington DC Integrated Hematology-Oncology Division, Director, The Ruesch Center for the Cure of GI Cancers, Frederick P. Smith Endowed Chair, CMO, Lombardi Comprehensive Cancer Center, Oncology CMO, Indivumed
Prof. Marco Novelli, MD, Consultant histopathologist and professor of gastrointestinal pathology, University College London Hospitals, Medical Director at HCA Laboratories, London, UK
Dr. Takayuki Yoshino, MD PhD, Director, Department of Gastroenterology and Gastrointestinal Oncology, Deputy Director, National Cancer Center Hospital East, Kashiwa, Japan
Jakob Nikolas Kather, MD MSc, Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany
Prof. Dr. med. Hans-Joachim Schmoll, MD, Head of Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/Oncology, University Hospital Halle, Germany
Prof. Marc Peeters, MD, CEO of the Antwerp University Hospital, Professor of Oncology at the Antwerp University, Belgium
Dr. Jeanine Roodhart, MD PhD
Dr. Frank Sinicrope, MD
More information about the SAB.
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefitting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, separating patients into distinct Low, Intermediate and High-risk groups to guide ACT treatment decisions. Data previously published in The Lancet and The Lancet Oncology showed that the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information about the Histotype Px Colorectal biomarker, please visit:
The Lancet publication.
The Lancet Oncology publication.
Contact:
Torbjørn Furuseth, MD
torbjorn.furuseth@domorediagnostics.com